CXCL12 and pulmonary arterial hypertension: Our experimental results suggest that if the CXCR4 inhibitor silibinin is used to ameliorate PAH prior to PAH becoming a severe and irreversible condition, the CXCR4/SDF-1 axis may be suppressed, leading to a reduction in pulmonary arterial pressure and pulmonary arteriolar occlusion.